Global Alzheimer’s Platform Foundation® (GAP) Condemns CMS Preliminary Coverage Decision on First Disease Modifying Drug for Alzheimer’s as Repudiation of President’s Promise to Advance Treatments for Alzheimer’s for all Americans

GAP calls for a traditional National Coverage Determination for ADUHELM consistent with past CMS decisions which will ensure access and equity for all patients stricken with Alzheimer’s. Washington, D.C. (January 11, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for […]

Read more »

Global Alzheimer’s Platform Foundation® Applauds Biogen for Reducing Cost of ADUHELM

GAP Renews Its Call for CMS to Cover the New Class of Drugs for the Treatment of Alzheimer’s Washington, D.C. (December 20, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on the […]

Read more »

Atlanta Metro Communities Gain Access to Renowned Alzheimer’s Research Network Through Local Clinical Trial Site

iResearch Atlanta will join the Global Alzheimer’s Platform Foundation®’s network (GAP-Net) of clinical trial sites working to bring new treatments to those living with the disease and and improve equity in research. Contact: Peter Buonanno – peterbuonanno@rational360.com – 704.989.5501 WASHINGTON, D.C. (December 7, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) announced that iResearch Atlanta […]

Read more »

Ixico and GAP Partner Interview

Watch GAP President John Dwyer and GAP’s Senior Advisor, Dr. Lynne Hughes, talk about our Ixico partnership and our Bio-Hermes study.

Read more »

Orlando Seniors Gain Access to Innovative Alzheimer’s Clinical Trial

Study leaders at new Global Alzheimer’s Network Site Commit to Improving Equity in Florida Alzheimer’s Research Contact: Peter Buonanno – peterbuonanno@rational360.com – 408-466-5952 Washington, DC (November 18, 2021) – With enrollment in full swing, the Global Alzheimer’s Platform Foundation® (GAP) has announced that K2 Medical Research will join both their GAP-Network of clinical trial sites […]

Read more »

Alzheimer’s Research Center Focused on Hispanics Opens in Texas

New GAP-Net site El Faro Health and Therapeutics has opened in Rio Grande City, TX. The below article was translated from Spanish to English. The original, Spanish version is linked at the bottom. A new clinical research center to study Alzheimer’s and its impact among Hispanics, the group with the highest prevalence of this disease […]

Read more »

Global Alzheimer’s Platform Foundation Announces First Private Alzheimer’s Clinical Research Site in Region with Highest Prevalence of Disease

Alzheimer’s World Directs Eyes on the Rio Grande Valley as Acclaimed Family Physician Opens New Facility in Rio Grande City with Highest Alzheimer’s Rate in the Country The Global Alzheimer’s Platform Foundation® (GAP) and Dr. Antonio Falcon celebrated the opening of El Faro Health & Therapeutics in Rio Grande City, TX on Saturday, marking a […]

Read more »

Renowned Father-Son Physician Duo to Bring First Alzheimer’s Clinical Trials to Rio Grande City

GAP-Net Site, El Faro Health and Therapeutics, was opened in Starr County, Texas led by Drs. Antonio and James Falcon. El Faro Health & Therapeutics will be the first private clinical research site in Starr County, TX. This groundbreaking initiative will bring critical Alzheimer’s-related research and care to a community that has been historically underrepresented […]

Read more »

Falcon: Clinical Trials to Focus on Alzheimer’s Crisis in Starr County

GAP is proud to support the grand opening of #GAPNet El Faro Health and Therapeutics, the first private research site in Starr County, Texas. Starr County is a 97% Hispanic Community with the highest prevalence of Alzheimer’s disease in America. Legendary Starr County physician and Baylor College of Medicine Trustee, Dr. Antonio ‘Tony’ Falcon is […]

Read more »

President Biden Just Called for Racial Equity in Alzheimer’s Care & Research. Here’s How ARPA-H Can Help Us Achieve This Goal

GAP President John Dwyer commends President Joe Biden on his commitment to fight Alzheimer’s, as well as calls on Congress to pass ARPA-H. Normally, presidential proclamations aren’t news. However, as the United States sinks deeper into a worsening Alzheimer’s public health crisis, President Joe Biden is making his priorities on the disease abundantly clear. Prior […]

Read more »

The Encouraging Progress of Diagnostics and Data Sharing in Dementia

Microsoft and Gates Ventures founder, Bill Gates, mentions GAP’s Bio-Hermes study to the World Dementia Council. We’ve all heard the statistics: Today, nearly 55 million people suffer from Alzheimer’s disease or related dementias. According to the WHO, dementia is the fastest growing burden on healthcare systems and the seventh leading cause of death worldwide. Its […]

Read more »

Global Alzheimer’s Platform Foundation (GAP) Taps Leading International Clinical Trial Expert for Senior Advisor Role

Washington, DC (November 10, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) welcomes Lynne Hughes, PhD, an international clinical trial research expert, as a Senior Advisor to the organization. Dr. Hughes will further expand GAP’s strength in developing global networks of clinical trial research institutions dedicated to accelerating the discovery of new assessments, treatments, and cures […]

Read more »

Memory Screening Helps Prevent Dementia, and You Can get it for Free Here in N.J.

Three GAP-Net Sites, The Cognitive and Research Center of New Jersey, Princeton Medical Institute, and Advanced Memory Research Institute of New Jersey are hosting a state wide FREE memory screening for individuals 50+. If you’re worried about the threat of dementia, there’s something you can do right now to reduce your risk. Get your memory […]

Read more »

To Beat Alzheimer’s, Tampa Seniors From Underserved Communities can get Involved in Clinical Trials

GAP-Net Site, Axiom Clinical Research of Florida, talks about the Bio-Hermes study and what people from traditionally underserved communities can do to get involved in research. We need an accessible means of diagnosing Alzheimer’s disease and research that demonstrates that new therapies and diagnostic tools work for all people. As a neurological researcher and an […]

Read more »

Breakthrough Alzheimer’s Clinical Trial Seeks to Include More Black and Diverse Volunteers

GAP’s Bio-Hermes study was featured in BlackNews.com about our groundbreaking commitment to diversity. Washington, DC — Research sites in Florida, Illinois, Kansas, Texas, and New York are now recruiting participants for The Global Alzheimer’s Platform Foundation® (GAP)’s Bio-Hermes Study – a breakthrough Alzheimer’s clinical trial searching for cost-effective methods to assess the signs of the disease. It is […]

Read more »

Federal Funding for Alzheimer’s Continues to Multiply at USC

GAP-Net site, the University of Southern California, received over 90 grants totaling $92 million in 2020. USC’s bench is deep and its scope is wide when it comes to research on Alzheimer’s disease. In Paul Thompson’s lab, researchers query a vast trove of brain images and DNA from all over the world to glean insights that would be […]

Read more »

Central Florida Neurologists Encourage the Black Community to Volunteer for Study of Alzheimer’s Assessment Tools

GAP’s Tamiko MaGee-Rodgers, Associate Director for Recruitment and Strategic Initiatives, wrote an article in the Orlando Times about the Black community getting involved in Alzheimer’s disease clinical trials and the Bio-Hermes study at GAP-Net site, Charter Research. At the Global Alzheimer’s Platform Foundation (GAP), our focus is speeding the delivery of innovative therapies to people […]

Read more »

Neurologists Encourage Blacks to Volunteer for Alzheimer’s Study

GAP-Net site, Progressive Medical Research, was featured in the Daytona Times for the Bio-Hermes study and how to get a free brain scan. The effects of Alzheimer’s disease on Black families across the U.S. are devastating. If nothing is done to mitigate these effects, according to researchers at Florida International University and UsAgainstAlzheimer’s, by 2030 […]

Read more »

Bio-Hermes Study Underway To Develop Cost-Effective Alzheimer’s Diagnostics

GAP President John Dwyer and GAP-Net site, Charter Research, were featured in Being Patient talking about the Bio-Hermes study, our commitment to diversity, and the tests used in the study. Scientists have made strides in improving the precision of diagnosing Alzheimer’s, but available diagnostic tools that measure Alzheimer’s biomarkers remain inaccessible for many patients. So, […]

Read more »

Neurologists Encourage Blacks to Volunteer for Alzheimer’s Study

GAP President John Dwyer and GAP-Net site, Axiom Clinical Research, were featured in the Florida Courier about the Bio-Hermes study and the importance of Black and African American participation in Alzheimer’s trials. The effects of Alzheimer’s Disease on the Black families across the U.S. are devastating. If nothing is done to mitigate these effects, according […]

Read more »

Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) to Partner with the Global Alzheimer’s Platform Foundation® (GAP) and Other Industry Leaders on Breakthrough Alzheimer’s Study

Contact: Peter Buonanno – peterbuonanno@rational360.com, 704-989-5501 WASHINGTON, D.C. (July 28, 2021) — Today, the Global Alzheimer’s Platform Foundation® (GAP) announced that Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) will join the list of biopharma, technology, and nonprofit partners who are contributing to GAP’s breakthrough Alzheimer’s study, Bio-Hermes. Bio-Hermes is the first-ever platform study […]

Read more »

Wash U Neurologist Explains Controversy Behind New Alzheimer’s Drug: Aduhelm

GAP-Net site Washington Univeristy in St. Louis’ Dr. Joy Snider about the pros and cons about the approval of Aduhelm (Aducanumab). The recent FDA approval of a new Alzheimer’s drug has some researchers concerned — aside from its $56,000-a-year price tag. It’s the first Alzheimer’s drug to be approved since 2003. It’s called aducanumab and is marketed […]

Read more »

GAP’s Dr. Tamiko MaGee-Rodgers Speaks About Minority Involvement in Clinical Trials

Dr. Tamiko Magee-Rodgers joins the BNC to discuss the new Alzheimer`s drug, Aduhelm, and the role of minorities in clinical trials. Originally shown on BNC on July 9, 2021.

Read more »

Local Researchers Help Black & Brown Communities Detect Factors for Alzheimer’s

GAP Net site, Great Lakes Clinical Trials, spoke The Chicago Defender about GAP’s Bio-Hermes study and the importance of minority communities getting involved in Alzheimer’s clinical trials. Chicago’s Great Lakes Clinical Trials is now enrolling volunteers with and without memory concerns in the Global Alzheimer’s Platform Foundation’s Bio-Hermes Study. The study seeks to evaluate how […]

Read more »
To top